Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ImClone Extends Deadline For Mystery Bidder

This article was originally published in The Pink Sheet Daily

Executive Summary

Name of bidder will be released whether ImClone accepts its offer or not.

ImClone has heightened the drama a notch in its potential acquisition by extending the deadline for its mystery bidder's due diligence.

ImClone had declined a roughly $4.5 billion, $60 per share, bid by Bristol-Myers Squibb Sept. 10, telling the Bristol board that it had in hand a $70 per share cash offer from an unnamed "large Pharma" firm, subject to due diligence (1 (Also see "Mystery Date: ImClone Rejects Bristol For Unnamed $70 Per Share Bidder" - Pink Sheet, 10 Sep, 2008.)).

The due diligence deadline was Sept. 28.

However, in a Sept. 29 release, the firm said, "the large Pharma company that had made an offer to acquire ImClone at $70 per share, subject to due diligence, but not financing, has informed ImClone that by 11:59 pm on Wednesday, October 1, 2008, they will either make a proposal, that is no longer subject to due diligence, or withdraw."

Bristol CEO James Cornelius and Carl Icahn, ImClone chairman, have traded barbs in letters over the past few weeks, with Cornelius upping its offer to $62 and per share while outlining a plan for a hostile bid.

Icahn responded that the offer "seems absurd."

In a move indicative of the escalating hostility in this negotiation, Bristol's lone representative, John Celentano, resigned from the ImClone board of directors Sept. 22.

Bristol and ImClone are partners in cancer drug Erbitux (cetuximab). Bristol already owns about 17 percent of ImClone shares.

ImClone said it would name the mystery bidder after the due diligence deadline, whether or not it accepts its offer. "As has been mutually agreed, if they withdraw and negotiations have thus been ended, the name for the company will be disclosed," according to the Sept. 29 release.

-Pamela Taulbee ([email protected])


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts